Artemis Medicare

Why is Artemis Medicare Services Ltd falling/rising?

As of 28-Aug, Artemis Medicare Services Ltd's stock price has risen to 319.30, reflecting a 0.73% increase, driven by strong performance, solid fundamentals, and a trend reversal after prior declines. The stock has outperformed the market significantly over the past month and year, despite a drop in investor participation.

As of 28-Aug, Artemis Medicare Services Ltd is experiencing a rise in its stock price, currently at 319.30, reflecting an increase of 2.3 points or 0.73%. This upward movement can be attributed to several factors highlighted in the recent performance data. Notably, the stock has shown a trend reversal, gaining after three consecutive days of decline, which indicates a potential recovery in investor sentiment.<BR><BR>The stock's performance over the past month has been particularly strong, with a 15.19% increase compared to a mere 0.65% rise in the Sensex, showcasing its ability to outperform the broader market. Additionally, the stock has delivered impressive returns year-to-date, up 17.82%, and has significantly outperformed the market over the past year with a 43.06% increase, while the Sensex has declined by 3.52%.<BR><BR>Moreover, the company has demonstrated strong fundamentals, including a low Debt to EBITDA ratio of 1.39 times, which indicates a solid ability to service its debt. The operating profit has grown at an annual rate of 33.45%, and the company has reported positive results for the last ten consecutive quarters. These factors contribute to a favorable outlook for the stock, enhancing its attractiveness to investors.<BR><BR>Despite a recent decline in investor participation, as indicated by a 48.28% drop in delivery volume, the stock remains liquid enough for trading, which may help sustain its price. Furthermore, the stock is close to its 52-week high, being only 4.23% away from Rs 334.05, which may encourage buying interest as investors look to capitalize on its upward momentum.<BR><BR>In summary, the rise in Artemis Medicare Services Ltd's stock price can be attributed to its strong recent performance, solid financial fundamentals, and a positive trend reversal, despite some concerns regarding reduced investor participation.

Which are the latest news on Artemis Medicare?

Who are in the management team of Artemis Medicare?

The management team of Artemis Medicare includes Managing Director Devlina Chakravarty, Chairman Onkar S Kanwar, and several directors, along with independent directors such as Deepa Gopalan Wadhwa and Sunil Tandon, bringing diverse expertise to the company.

The management team of Artemis Medicare includes the following individuals:<BR><BR>1. **Devlina Chakravarty** - Managing Director<BR>2. **Onkar S Kanwar** - Chairman & Director<BR>3. **Shalini Kanwar Chand** - Director<BR>4. **Neeraj Kanwar** - Director<BR>5. **Nirmal Kumar Ganguly** - Director<BR>6. **Poonam Makkar** - Company Secretary & Compliance Officer<BR><BR>Additionally, there are several independent directors on the board:<BR><BR>1. **Deepa Gopalan Wadhwa** - Independent Director<BR>2. **Sunil Tandon** - Independent Director<BR>3. **S Narayan** - Independent Director<BR>4. **Sanjaya Baru** - Independent Director<BR>5. **Sanjib Sen** - Independent Director<BR><BR>This diverse team brings a range of expertise and leadership to the company.

What does Artemis Medicare do?

Artemis Medicare Services Ltd operates multi-specialty hospitals and was established in 2004, with its first hospital opening in 2007. As of June 2026, it reported net sales of 287 Cr and a net profit of 31 Cr, with a market cap of INR 5,086 Cr.

Overview: <BR>Artemis Medicare Services Ltd is engaged in managing and operating multi-specialty hospitals within the hospital industry and falls under the small-cap market category.<BR><BR>History: <BR>The company was incorporated on May 18, 2004, and commenced commercial operations by establishing Artemis Hospital (formerly Artemis Health Institute) in Gurugram on July 16, 2007. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 287 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 31 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 5,086 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 44.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.14% <BR>Debt-Equity: 0.06 <BR>Return on Equity: 11.33% <BR>Price to Book: 5.44<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Artemis Medicare?

Peers of Artemis Medicare include Health.Global, Jupiter Life Lin, Yatharth Hospital, and others. Artemis Medicare shows good growth and a solid capital structure, with a 1-year return of 31.91%, while KMC Speciality leads with an 80.93% return.

Peers: The peers of Artemis Medicare are Health.Global, Jupiter Life Lin, Yatharth Hospit., Jeena Sikho, Kovai Medical, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, Shalby, and GPT Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jupiter Life Lin and Kovai Medical, while Average management risk is found at Health.Global, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, and Shalby, and the rest. Good growth is seen at Artemis Medicare, Health.Global, Indrapr.Medical, and Jeena Sikho, while Average growth is found at Yatharth Hospit. and Kovai Medical, and the rest. Below Average growth is noted at Jupiter Life Lin and Shalby. Excellent capital structure is present at Jupiter Life Lin, Yatharth Hospit., Jeena Sikho, Indrapr.Medical, and KMC Speciality, while Good capital structure is seen at Artemis Medicare and Kovai Medical, and the rest. Below Average capital structure is noted at Health.Global and Dr Agarwal's Eye.<BR><BR>Return Snapshot: KMC Speciality has the highest 1-year return at 80.93%, while Indrapr.Medical has the lowest at -20.64%. Artemis Medicare's 1-year return of 31.91% is significantly higher than Indrapr.Medical's but lower than KMC Speciality's. Additionally, Indrapr.Medical, Jeena Sikho, and Shalby have negative six-month returns.

How big is Artemis Medicare?

As of 14th August, Artemis Medicare Services Ltd has a market capitalization of 4,972.40 Cr, with recent net sales of 1,113.60 Cr and a net profit of 113.65 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Artemis Medicare Services Ltd has a market capitalization of 4,972.40 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,113.60 Cr, while the sum of Net Profit for the same period is 113.65 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 934.71 Cr and Total Assets totaling 1,428.65 Cr.

Are Artemis Medicare Services Ltd latest results good or bad?

Artemis Medicare Services Ltd's latest Q1 FY27 results are strong, with a net profit of ₹31.31 crores (up 47.13% year-on-year) and revenue of ₹287.32 crores (up 12.69%). The company also improved its operating margin to 19.64% and has seen its stock rise 41.86% over the past six months, indicating positive performance overall.

Artemis Medicare Services Ltd's latest results for Q1 FY27 are quite strong, indicating a positive performance overall. The company reported a net profit of ₹31.31 crores, which reflects a significant year-on-year growth of 47.13%. Additionally, revenue reached ₹287.32 crores, marking a 12.69% increase compared to the same quarter last year.<BR><BR>The operating margin improved to 19.64%, the highest in the last eight quarters, showcasing enhanced operational efficiency. The profit after tax (PAT) margin also expanded to 10.94%, up from 8.32% in the previous year, indicating that the company is effectively converting revenue growth into profit.<BR><BR>Moreover, Artemis Medicare's stock has performed exceptionally well, gaining 41.86% over the past six months, significantly outperforming the Sensex, which declined during the same period. This performance, combined with improving profitability metrics and a conservative balance sheet, suggests that the company's results are indeed good and reflect a strong operational momentum.

Should I buy, sell or hold Artemis Medicare Services Ltd?

When is the next results date for Artemis Medicare Services Ltd?

The next results date for Artemis Medicare Services Ltd is February 2, 2026.

The next results date for Artemis Medicare Services Ltd is scheduled for February 2, 2026.

Is Artemis Medicare technically bullish or bearish?

As of December 2, 2025, the trend has shifted to bullish with moderate strength, supported by positive indicators like the MACD, RSI, and moving averages, although caution is advised due to some bearish signals on the monthly timeframe.

As of 2 December 2025, the technical trend has changed from mildly bearish to bullish. The current stance is bullish with moderate strength. Key indicators driving this include a bullish MACD on the weekly chart, a bullish RSI on the monthly chart, and bullish signals from moving averages on the daily timeframe. The KST and OBV are also bullish on the weekly timeframe, while the Bollinger Bands show a mildly bullish trend. However, the monthly MACD and KST remain mildly bearish, indicating some caution. Overall, the bullish trend is supported by recent price action, despite a recent decline from the previous close.

How has been the historical performance of Artemis Medicare?

Artemis Medicare has shown consistent growth, with net sales increasing from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025, and profit after tax rising from INR 31.40 crore to INR 82.18 crore during the same period. The company has improved its operating profit margin and cash flow, indicating strong operational efficiency.

Answer:<BR>The historical performance of Artemis Medicare shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Artemis Medicare's net sales have increased significantly from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar pattern, rising from INR 554.80 crore in March 2022 to INR 936.92 crore in March 2025. Operating profit (PBDIT) also saw substantial growth, climbing from INR 71.35 crore in March 2022 to INR 184.78 crore in March 2025, with an operating profit margin that improved from 12.16% to 16.2% over the same period. Profit before tax increased from INR 37.18 crore in March 2022 to INR 107.67 crore in March 2025, and profit after tax rose from INR 31.40 crore to INR 82.18 crore. The company's total assets grew from INR 709.66 crore in March 2022 to INR 1,357.41 crore in March 2025, while total liabilities increased from INR 709.66 crore to INR 1,357.41 crore as well. Cash flow from operating activities improved from INR 59 crore in March 2022 to INR 145 crore in March 2025, indicating enhanced operational efficiency. Overall, Artemis Medicare has demonstrated robust growth in sales, profits, and asset base, positioning itself favorably in the market.

Is Artemis Medicare overvalued or undervalued?

As of October 16, 2025, Artemis Medicare is considered fairly valued with a PE ratio of 38.36 and a favorable comparison to peers like Apollo Hospitals and Max Healthcare, despite a recent underperformance against the Sensex, but it shows strong long-term growth potential.

As of 16 October 2025, Artemis Medicare's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 38.36, an EV to EBITDA of 20.65, and a PEG ratio of 0.72, which suggests a reasonable growth expectation relative to its price.<BR><BR>In comparison to its peers, Artemis Medicare's valuation appears more favorable. For instance, Apollo Hospitals, which is also rated attractive, has a significantly higher PE ratio of 71.71, while Max Healthcare is categorized as very expensive with a PE of 94.88. Despite recent underperformance compared to the Sensex, with a year-to-date return of -23.26% versus the Sensex's 6.82%, Artemis Medicare's strong growth in the long term, as evidenced by a 273.78% return over three years, reinforces its attractiveness in the market.

Who are the top shareholders of the Artemis Medicare?

The top shareholder of Artemis Medicare is Constructive Finance Private Limited, holding 67.17%. Other significant shareholders include the Governor of Kerala at 4.91%, mutual funds at 1.96%, foreign institutional investors at 0.31%, and individual investors with a collective stake of 12.86%.

The top shareholders of Artemis Medicare primarily include the promoters, with Constructive Finance Private Limited holding the highest stake at 67.17%. The promoters collectively have a significant portion of the shares, with 44.53% of their holdings pledged. In terms of public shareholders, the Governor of Kerala is the largest, holding 4.91%. Additionally, mutual funds hold 1.96% across four schemes, while foreign institutional investors (FIIs) have a smaller stake of 0.31% through 24 different entities. Individual investors collectively own 12.86% of the company.

Has Artemis Medicare declared dividend?

Artemis Medicare Services Ltd has declared a 45% dividend, amounting to 0.45 per share, with an ex-date of July 5, 2024. Despite a recent 6-month price return of -21.46%, the company has shown strong total returns over longer periods, particularly a 1358.88% total return over the past 5 years.

Artemis Medicare Services Ltd has declared a 45% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 45%<BR>- Amount per share: 0.45<BR>- Ex-date: 05 Jul 24<BR><BR>Dividend Yield: 0.16%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -21.46%, with a dividend return of 0%, resulting in a total return of -21.46%.<BR><BR>Over the past year, the price return was 53.3%, with a dividend return of 0.25%, leading to a total return of 53.55%.<BR><BR>In the 2-year period, the price return was 205.4%, with a dividend return of 0.88%, culminating in a total return of 206.28%.<BR><BR>For the 3-year period, the price return was 472.81%, with a dividend return of 2.26%, resulting in a total return of 475.07%.<BR><BR>In the last 4 years, the price return was 860.16%, with a dividend return of 2.87%, leading to a total return of 863.03%.<BR><BR>Finally, over the past 5 years, the price return was 1353.8%, with a dividend return of 5.08%, resulting in a total return of 1358.88%.<BR><BR>Overall, Artemis Medicare has shown significant total returns over the years, particularly in the longer term, despite a recent negative price return in the last 6 months. The declared dividend indicates a commitment to returning value to shareholders, although the yield remains relatively low.